Sun Acquisitions

AUGUST 22, 2024

Larger, consolidated companies can negotiate better terms with suppliers, secure more favorable contracts, and reduce per-unit production costs. Leveraging Economies of Scale M&A can enable companies to achieve economies of scale, reducing costs and improving efficiency.

M&A 52

M&A Management Mergers and Acquisitions Food 52

Growth Business

MARCH 4, 2024

In many ways, this is a good thing that will help the pharmaceutical industry detect and understand disease. What AI is doing for us now AI is already able to drive vehicles and negotiate obstacles. With so many resources being dedicated to its development and no real obstacles predicted, its rapid development is set to continue.

IT 52

IT Boutique Bank Banking 52

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Devensoft

MAY 25, 2023

From identifying the right targets to negotiating deals and integrating teams, there are several critical steps involved in executing a successful restructuring plan. For instance, a pharmaceutical company may acquire a smaller biotech firm to gain access to its research and development pipeline. 

Corporation 52

Corporation Mergers Mergers and Acquisitions Acquisitions 52

Peak Frameworks

SEPTEMBER 19, 2023

For example, while a pharmaceutical company focused solely on shareholder value might prioritize high-margin drugs for rare conditions, a stakeholder-oriented approach might consider affordability and broader societal health needs , as seen with Gilead's approach to its HIV medications.

Corporation 52

Corporation Private Equity Mergers and Acquisitions Corporate Finance 52

Cooley M&A

FEBRUARY 8, 2018

Approval of gross-ups in connection with a transaction typically involves a prior negotiation with the buyer. Nevertheless, as gross-up arrangements are typically negotiated after the deal price is negotiated, we do not believe that these arrangements are impacting overall stockholder consideration.

M&A 52

M&A Mergers and Acquisitions Mergers Negotiation 52

Cooley M&A

OCTOBER 29, 2018

In April 2017, Fresenius agreed to acquire Akorn, a US-based, Nasdaq-listed specialty manufacturer and marketer of generic prescription and over-the-counter pharmaceutical products, for $35 per share or approximately $4.75 The Merger Agreement.

Mergers and Acquisitions 52

Mergers and Acquisitions Mergers Business Pharmaceutical 52

Cooley M&A

APRIL 7, 2017

The court agreed with Gilead, based primarily on a review of the parties’ drafting and negotiating history, which was corroborated by the parties’ contemporaneous statements made after the European Commission approved the deal. Throughout the trial, it was evident that the word had various meanings during the negotiations.

Mergers and Acquisitions 40

Mergers and Acquisitions Negotiation Pharmaceutical IT 40

Cooley M&A

JULY 10, 2017

However, while by no means perfect, the buyer can negotiate for indemnification from the sellers for losses incurred in connection with the offering and sale of the security (both to the sellers and to a subsequent transferee). acquisitions of pharmaceutical products with clinical, regulatory and/or net sales milestones).

Securities 52

Securities IT Investors M&A 52

Software Equity Group

JANUARY 22, 2024

Virtual Reality : Virtual reality (VR), augmented reality (AR), and mixed reality (MR) have advanced well beyond video games and are now helping professional in many industries (including healthcare and pharmaceuticals) visualize important information in three-dimensional space.

Healthcare 52

Healthcare M&A Valuation Medical 52

Software Equity Group

JANUARY 22, 2024

Virtual Reality : Virtual reality (VR), augmented reality (AR), and mixed reality (MR) have advanced well beyond video games and are now helping professional in many industries (including healthcare and pharmaceuticals) visualize important information in three-dimensional space.

Healthcare 52

Healthcare M&A Valuation Medical 52

Cooley M&A

JUNE 10, 2020

The panel kicked off with a discussion about what types of assets pharmaceutical buyers tend to gravitate toward – both from a general market perspective and from the more specific view of Horizon. Key areas of interest for buyers and investors. rheumatology, nephrology, ophthalmology and endocrinology) and diseases within those areas.

M&A 40

M&A Medical Acquisitions Business 40

Devensoft

AUGUST 24, 2023

Through financial synergy, organizations can access new funding sources, negotiate better terms with suppliers or customers, and optimize their capital structure. By centralizing operations, leveraging economies of scale, and negotiating better terms with suppliers, organizations can achieve significant cost savings.

Business 52

Business Collaboration Mergers and Acquisitions Management 52

Cooley M&A

JANUARY 20, 2022

1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Growth Business

OCTOBER 2, 2023

With potential to be rolled out across numerous sectors, including pharmaceuticals, consumer electronics and cosmetics, this form of retail tech is likely to attract significant venture investment over the next 12 months. This is not just a legal necessity. Tim Bird is a corporate partner and a member of the VC practice at Fieldfisher.

Finance 52

Finance Finance Capital Funds 52

Cooley M&A

FEBRUARY 15, 2017

The continued publicity and political focus on drug pricing has created uncertainty in valuing specialty pharmaceutical and biotech companies. Negotiating Anti-Reliance Language. Life sciences exits were way down in 2016, as many acquirers stood on the sidelines awaiting the outcome (and now, effect) of the US presidential election.

M&A 40

M&A IPO Pharmaceutical Valuation 40

MergersCorp M&A International

NOVEMBER 16, 2024

firms, particularly in technology and pharmaceuticals, sectors that are considered critical to America’s future economic competitiveness. As companies strategically approached M&A opportunities, they had to be increasingly aware of potential regulatory pushback, which put added pressure on deal structures and negotiations.

Mergers and Acquisitions 52

Mergers and Acquisitions Mergers Acquisitions M&A 52

Cooley M&A

JANUARY 21, 2022

Congress targets pharmaceutical industry pricing and business practices. On December 10, 2021, the US House of Representatives Committee on Oversight and Reform released a 269-page report publishing findings from a three-year investigation into the pharmaceutical industry.

Mergers and Acquisitions 40

Mergers and Acquisitions Mergers Pharmaceutical IT 40

Cooley M&A

JANUARY 18, 2017

The potential of significantly increased penalties will likely bring parties to the negotiating table. Antitrust focus on pharmaceutical industry expected to continue in 2017. The antitrust agencies are also likely to continue paying attention to pharmaceutical pricing.

Mergers and Acquisitions 52

Mergers and Acquisitions Pharmaceutical Mergers Investment 52